TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20084712

Group type: EXPERIMENTAL
Intervention: Single fraction of 8 Gy (SF group)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy of 40 Gy in 20 fractions (CF group)
Number of subjects: 107
Study: 16116682

Group type: EXPERIMENTAL
Intervention: Nebulized fluticasone propionate (FP) 250 mcg twice daily for 10 days
Number of subjects: 168

Group type: COMPARATOR
Intervention: Nebulized budesonide (BUD) 500 mcg twice daily for 10 days
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Both FP and BUD
Number of subjects: 168
Study: 12325104

Group type: EXPERIMENTAL
Intervention: New therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 10466475

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily (n = 9)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg twice daily (n = 8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 8647483

Group type: EXPERIMENTAL
Intervention: Women postpartum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Newborns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women postpartum (after 42 weeks of gestation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newborns (born after 42 weeks of gestation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women (before 38 weeks of gestation)
Number of subjects: 0
Study: 2192585

Group type: EXPERIMENTAL
Intervention: Captopril, 25 mg administered orally
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 526401

Group type: EXPERIMENTAL
Intervention: Diazoxide 300 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Labetalol 150 mg
Number of subjects: 5
Study: 31000180

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: S (‐) amlodipine (2.5 mg)
Number of subjects: 27
Study: 26938750

Group type: EXPERIMENTAL
Intervention: Sildenafil OSF 100 mg formulations
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sildenafil citrate 100 mg tablets
Number of subjects: 18
Study: 25870478

Group type: EXPERIMENTAL
Intervention: Early nutrition
Number of subjects: 154

Group type: COMPARATOR
Intervention: Late nutrition
Number of subjects: 154
Study: 23681047

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam suppositories
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 21624736

Group type: EXPERIMENTAL
Intervention: NT-proBNP measured at 3 months after myocardial infarction
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: NT-proBNP measured at 3 days after myocardial infarction
Number of subjects: 160

Group type: COMPARATOR
Intervention: NT-proBNP measured at 3 months compared to 3 days
Number of subjects: 160
Study: 19213575

Group type: EXPERIMENTAL
Intervention: Interscalene continuous infusion of 2% ropivacaine (2 mL/h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subacromial continuous infusion of 2% ropivacaine (2 mL/h)
Number of subjects: 40
Study: 16933001

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 130

Group type: COMPARATOR
Intervention: Prokinetics
Number of subjects: 130
Study: 15123230

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (160/4.5 microg, 1 or 2 inhalations; Symbicort Turbuhaler)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (1 inhalation)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (2 inhalations)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (1 or 2 inhalations)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (50/250 microg; Seretide Diskus)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 10516704

Group type: EXPERIMENTAL
Intervention: Unrelated bone marrow donors
Number of subjects: 27
Study: 7720476

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15 mg/kg, single intravenous dose)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 22
Study: 2297461

Group type: COMPARATOR
Intervention: 2 mg oral loperamide (4 doses)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 16 mg oral loperamide (1 dose)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 16 mg oral loperamide (2 doses)
Number of subjects: 19
Study: 7247321

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (NF)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Methenamine hippurate (MH)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no prophylactic urinary tract disinfectant)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (NF) and Methenamine hippurate (MH)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 123
Study: 30711321

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Daily dressing
Number of subjects: 114

Group type: COMPARATOR
Intervention: Weekly dressing
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control (regular pin site care)
Number of subjects: 114
Study: 28668770

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 104
Study: 24700581

Group type: EXPERIMENTAL
Intervention: Immediate-release opioid (oxycodone or morphine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21705873

Group type: EXPERIMENTAL
Intervention: CUIDATE group (multidimensional physical therapy program)
Number of subjects: 44
Study: 20811491

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (six 2-hour group sessions focused on reducing substance use and sexual risk behavior)
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Attention-control group (six 2-hour group sessions of videos and discussion of MSM community issues unrelated to substance use, sexual risk, and HIV/AIDS)
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Nonrandomized standard HIV-testing group (received standard HIV counseling and testing)
Number of subjects: 1686
Study: 17073863

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 41
Study: 15860763

Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 0
Study: 11899582

Group type: EXPERIMENTAL
Intervention: 10-week physical training
Number of subjects: 1200
Study: 10233317

Group type: EXPERIMENTAL
Intervention: MPD regimen starting with 50% of the minimal phototoxic dose (MPD) with weekly increments of 40%, 30%, 25%, 20%, 15%, 10% and 5% to a maximum of 14.5 J/cm2
Number of subjects: 85

Group type: COMPARATOR
Intervention: Skin type regimen starting with a fixed dose based on skin type with weekly dose increments of 40%, decreasing to 20% once erythema develops
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both treatment groups (MPD and skin type regimen)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: MPD regimen
Number of subjects: 85
Study: 7723453

Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subject-based approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elimination of time
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calculation of the mean of available data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quality-adjusted survival analysis
Number of subjects: 0
Study: 2178759

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Plasma exchange for multiple sclerosis
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Plasma exchange for thrombotic thrombocytopenic purpura
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Plasma exchange for rapidly progressive glomerulonephritis
Number of subjects: 700
Study: 6259925

Group type: EXPERIMENTAL
Intervention: Vegetables
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Breakfast cereals
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cereals and biscuits
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fruit
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dairy products
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dried legumes
Number of subjects: 62

Group type: COMPARATOR
Intervention: Fat
Number of subjects: 62

Group type: COMPARATOR
Intervention: Protein
Number of subjects: 62

Group type: COMPARATOR
Intervention: Fiber
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sugar content
Number of subjects: 62
Study: 31795967

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 150
Study: 28182820

Group type: EXPERIMENTAL
Intervention: 1000 mg Resveratrol (RSVhigh)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 150 mg Resveratrol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 26104542

Group type: COMPARATOR
Intervention: Radiotherapy only (RT)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 198

Group type: COMPARATOR
Intervention: Surgery + Radiotherapy (RT)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Complete resection
Number of subjects: 198

Group type: COMPARATOR
Intervention: Partial resection
Number of subjects: 198

Group type: COMPARATOR
Intervention: Total resection
Number of subjects: 198
Study: 24314824

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Groningen Frailty Indicator (GFI)
Number of subjects: 78
Study: 22000728

Group type: EXPERIMENTAL
Intervention: Dialysate tCa concentration of 3.0 mEq/L
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dialysate tCa concentration of 2.75 mEq/L
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dialysate tCa concentration of 2.5 mEq/L
Number of subjects: 22
Study: 19199349

Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: No axillary dissection or radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Axillary treatment (dissection or radiotherapy)
Number of subjects: 0
Study: 17356153

Group type: EXPERIMENTAL
Intervention: Continuous passive movement machine
Number of subjects: 27
Study: 15373934

Group type: EXPERIMENTAL
Intervention: Formoterol (4.5 microg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Terbutaline (500 microg)
Number of subjects: 20
Study: 11198486

Group type: EXPERIMENTAL
Intervention: Patients with dumping
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Patients without dumping
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy control patients
Number of subjects: 44
Study: 9011463

Group type: EXPERIMENTAL
Intervention: MS patients with increased intestinal permeability
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CD45RO expression on CD20+ B cells in MS patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coincident MS and UC patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20

Group type: COMPARATOR
Intervention: Patients with Crohn's disease
Number of subjects: 20
Study: 1504890

Group type: EXPERIMENTAL
Intervention: Acarosan (acaricidal cleaner)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intensive cleaning (control)
Number of subjects: 20
Study: 6319338

Group type: EXPERIMENTAL
Intervention: VCA-IgA
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: VCA-IgG
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: EA-IgA
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: EA-IgG
Number of subjects: 200

Group type: COMPARATOR
Intervention: EA-IgA, EA-IgG, VCA-IgG
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: VCA-IgA, VCA-IgG, EA-IgA, EA-IgG
Number of subjects: 200
Study: 31098832

Group type: EXPERIMENTAL
Intervention: 25 mL of 6% CHO mouth rinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA) mouth rinse
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHO mouth rinse
Number of subjects: 12
Study: 27128776

Group type: EXPERIMENTAL
Intervention: Bipolar laparoscopic loop and bipolar morcellator
Number of subjects: 124

Group type: COMPARATOR
Intervention: Monopolar hook and conventional mechanical morcellator
Number of subjects: 124
Study: 26586448

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study: 24833043

Group type: EXPERIMENTAL
Intervention: bilastine (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: hydroxyzine (25 mg)
Number of subjects: 12
Study: 22252289

Group type: EXPERIMENTAL
Intervention: Coroflex(®) Please stents (B. Braun, Melsungen, Germany)
Number of subjects: 95
Study: 19569964

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine
Number of subjects: 2022
Study: 17848496

Group type: EXPERIMENTAL
Intervention: Intention-to-treat (ITT) analysis
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Modified ITT
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Violation of ITT
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Unclear ITT approach
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Missing data
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Loss to follow-up
Number of subjects: 403
Study: 15165613

Group type: EXPERIMENTAL
Intervention: L-ornithine alpha-ketoglutarate (OKG) 10 g/d for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (isonitrogenous)
Number of subjects: 46
Study: 11265953

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Support groups
Number of subjects: 278

Group type: COMPARATOR
Intervention: Natural course
Number of subjects: 278
Study: 9597564

Group type: EXPERIMENTAL
Intervention: Chlorzoxazone 250 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chlorzoxazone 750 mg
Number of subjects: 16
Study: 7905550

Group type: EXPERIMENTAL
Intervention: More-effective treatments (6 or more cycles of cyclophosphamide, methotrexate, fluorouracil and prednisone; with or without tamoxifen, or tamoxifen and prednisone alone)
Number of subjects: 2108

Group type: COMPARATOR
Intervention: Less-effective treatments (no treatment or a single cycle of chemotherapy)
Number of subjects: 2108
Study: 3266449

Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg, intravenous)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Induction of neuroleptanalgesia
Number of subjects: 50
Study: 31982148

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg SC every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg SC every 4 weeks
Number of subjects: 0
Study: 31570429

Group type: EXPERIMENTAL
Intervention: Docetaxel treatment in variant carriers (ANO7 rs77559646)
Number of subjects: 0
Study: 28538831

Group type: EXPERIMENTAL
Intervention: Laryngeal Manual Therapy (LMT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 20
Study: 24871960

Group type: EXPERIMENTAL
Intervention: Website training on safety with dogs for 2 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control website on transportation safety for 2 weeks
Number of subjects: 68
Study: 23379785

Group type: EXPERIMENTAL
Intervention: High-bolus-dose tirofiban
Number of subjects: 383

Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 383
Study: 21234549

Group type: EXPERIMENTAL
Intervention: AZD3783 (1-40 mg oral doses)
Number of subjects: 9
Study: 19899372

Group type: EXPERIMENTAL
Intervention: Standardized mammotest every 2 years
Number of subjects: 0
Study: 18293707

Group type: EXPERIMENTAL
Intervention: Levocetirizine (LCZ) 5 mg p.o.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15031430

Group type: EXPERIMENTAL
Intervention: Early imaging (MR or CT)
Number of subjects: 782

Group type: COMPARATOR
Intervention: Delayed selective imaging
Number of subjects: 782
Study: 12418583

Group type: EXPERIMENTAL
Intervention: telithromycin 800 mg once daily (qd) for 5 days
Number of subjects: 325

Group type: COMPARATOR
Intervention: amoxicillin/clavulanate 500/125 mg three times daily (tid) for 10 days
Number of subjects: 325
Study: 10080588

Group type: EXPERIMENTAL
Intervention: BR96‐doxorubicin conjugate 700 mg/m2 IV over 24 hours
Number of subjects: 23

Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m2 every 3 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: BR96‐doxorubicin conjugate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 23
Study: 7549121

Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cells Collection (PBSCC)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Bone Marrow Collection (BMC)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PBSCC with femoral catheter
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PBSCC without femoral catheter
Number of subjects: 65
Study: 2256010

Group type: EXPERIMENTAL
Intervention: Physician's usual advice to stop smoking + signed agreement + health visitor visits + letters of encouragement
Number of subjects: 2854

Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 2854

Group type: EXPERIMENTAL
Intervention: Advice supplemented by signed agreement
Number of subjects: 2854

Group type: EXPERIMENTAL
Intervention: Advice supplemented by letters of encouragement
Number of subjects: 2854

Group type: EXPERIMENTAL
Intervention: Advice supplemented by signed agreement and letters of encouragement
Number of subjects: 2854
Study: 6998872

Group type: EXPERIMENTAL
Intervention: 50 mg spironolactone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 100 mg spironolactone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 200 mg spironolactone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 29722252

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.07g/kg/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 28591833

Group type: EXPERIMENTAL
Intervention: Follitropin epsilon (25, 75, 150, and 300 IU)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Follitropin epsilon (75 IU or 150 IU once daily, or 150 IU every other day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: 150 IU Gonal-f
Number of subjects: 76

Group type: COMPARATOR
Intervention: 150 IU Bravelle
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Follitropin epsilon (150 IU)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: All doses of follitropin epsilon
Number of subjects: 76
Study: 25692781

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 2889

Group type: COMPARATOR
Intervention: Diabetes mellitus support and education (DSE)
Number of subjects: 2889
Study: 23525779

Group type: EXPERIMENTAL
Intervention: Telephone-based osteoarthritis self-management support intervention
Number of subjects: 515

Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 515
Study: 21343332

Group type: EXPERIMENTAL
Intervention: Postcard intervention (nine postcards sent over 12 months)
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 2300
Study: 19563497

Group type: EXPERIMENTAL
Intervention: Continuous etanercept therapy (25 mg SC BIW throughout 54 weeks)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Paused etanercept therapy (50 mg SC BIW for up to 12 weeks, then 25 mg BIW upon retreatment)
Number of subjects: 711

Group type: COMPARATOR
Intervention: Continuous etanercept therapy
Number of subjects: 711

Group type: COMPARATOR
Intervention: Paused etanercept therapy
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Both continuous and paused etanercept treatment
Number of subjects: 711
Study: 17689601

Group type: EXPERIMENTAL
Intervention: PP-CVD course (2-month course on Primary Prevention of Adult Cardiovascular Disease)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 280
Study: 15390313

Group type: EXPERIMENTAL
Intervention: Prophylactic ciprofloxacin after delayed intensification (DI) courses
Number of subjects: 69

Group type: COMPARATOR
Intervention: Historical controls (no prophylactic ciprofloxacin)
Number of subjects: 69
Study: 11737129

Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 15

Group type: COMPARATOR
Intervention: Long-pulsed Nd:YAG laser
Number of subjects: 15
Study: 9298132

Group type: EXPERIMENTAL
Intervention: Urinary excretion of 5-S-cysteinyldopa (5-S-CD)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Urinary excretion of 5-S-cysteinyldopa (5-S-CD) > 1,000 micrograms/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Urinary excretion of 5-S-cysteinyldopa (5-S-CD) > 10,000 micrograms/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Urinary excretion of 5-S-cysteinyldopa (5-S-CD) > 40,000 micrograms/day
Number of subjects: 50
Study: 8370861

Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) biofeedback
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Conservative medical treatment
Number of subjects: 78
Study: 2873379

Group type: EXPERIMENTAL
Intervention: Atenolol (5-10 mg iv immediately, followed by 100 mg/day orally for 7 days)
Number of subjects: 16027

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 16027
Study: 30637862

Group type: EXPERIMENTAL
Intervention: Active sTMS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham sTMS
Number of subjects: 0
Study: 28616715

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab without anterior chamber paracentesis (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravitreal injection of bevacizumab with anterior chamber paracentesis (group B)
Number of subjects: 90
Study: 25573272

Group type: EXPERIMENTAL
Intervention: 6-month supplementation with omega 3&6 and antioxidants
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120